文献速递浆细胞疾病

靶向色氨酸分解代谢犬尿氨酸通路增强多发性骨髓瘤抗肿瘤免疫与细胞毒性

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.
PubMed 文献 · Leukemia · 2019-08-28

本研究探讨浆细胞样树突状细胞(pDC)与多发性骨髓瘤(MM)细胞相互作用上调免疫抑制性色氨酸分解代谢犬尿氨酸(Kyn)通路,尤其KMO酶上调。利用患者自体pDC-T-NK-MM共培养模型,药理学阻断KMO可激活pDC并触发MM特异性细胞毒性T淋巴细胞(CTL)和NK细胞对肿瘤细胞的杀伤活性;同时抑制Kyn通路和PD-L1可增强抗肿瘤免疫与细胞毒性。临床前数据为靶向KMO单独或联合抗PD-L1抗体恢复抗MM免疫应答提供依据。

要点

  • pDC与MM细胞相互作用上调免疫抑制性Kyn通路,尤其KMO酶。
  • 药理学阻断KMO激活pDC并增强CTL和NK细胞对MM细胞的杀伤。
  • 同时抑制Kyn通路和PD-L1可进一步增强抗肿瘤免疫与细胞毒性。

核心结论

  • 靶向Kyn通路酶KMO可增强抗MM免疫与细胞毒性,为新型免疫治疗提供临床前依据。

研究设计与样本

  • 利用基因表达谱(GEP)分析pDC-MM相互作用,并在患者自体pDC-T-NK-MM共培养模型中进行药理学阻断实验。

主要发现

  • pDC-MM相互作用触发免疫抑制性色氨酸分解代谢Kyn通路上调,KMO酶在相互作用中上调。
  • 药理学阻断KMO激活pDC并触发MM特异性CTL和NK细胞对肿瘤细胞的杀伤活性。
  • 同时抑制Kyn通路和PD-L1增强抗肿瘤免疫与细胞毒性。

临床怎么用

  • 临床前数据支持靶向KMO单独或联合抗PD-L1抗体作为恢复抗MM免疫应答的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our prior studies showed that dysfunctional plasmacytoid dendritic cells (pDCs) contribute to multiple myeloma (MM) pathogenesis. Specifically, pDC interactions with tumor and T/NK effector cells in the bone marrow (BM) milieu induce immune suppression and MM cell proliferation. Delineation of the mechanism(s) mediating pDC-MM-T-NK cell interactions will identify novel therapeutic targets to both enhance cytotoxicity and anti-MM immunity. Here, we utilized gene expression profiling (GEP) to show that pDC-MM interactions trigger upregulation of immunosuppressive tryptophan catabolic kynurenine (Kyn) pathway. In particular, we show that Kyn pathway enzyme kynurenine-3-monooxygenase (KMO) is upregulated during pDC-MM interactions. Using our coculture models of patient autologous pDC-T-NK-MM cells, we show that pharmacological blockade of KMO activates pDCs and triggers both MM-specific cytotoxic T-cell lymphocytes (CTL) and NK cells cytolytic activity against tumor cells. Furthermore, we show that simultaneous inhibition of Kyn pathway and immune checkpoint PD-L1 enhances antitumor immunity and cytotoxicity in MM. Our preclinical data therefore provide the basis for novel immune-based therapeutic approaches targeting Kyn metabolic pathway enzyme KMO, alone or in combination with anti-PD-L1 Ab, to restore anti-MM immune responses in MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ray A, Song Y, Du T, et al. Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2019. PMID: 31462737. doi:10.1038/s41375-019-0558-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。